Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

WEE1 inhibition in pancreatic cancer cells is dependent on DNA repair status in a context dependent manner.

Scientific reports - 12 Sept 2016

Lal Shruti, Zarei Mahsa, Chand Saswati N, Dylgjeri Emanuela, Mambelli-Lisboa Nicole C, Pishvaian Michael J, Yeo Charles J, Winter Jordan M, Brody Jonathan R

Abstract excerpt

Pancreatic ductal adenocarcinoma (PDA) is a lethal disease, in part, because of the lack of effective targeted therapeutic options. MK-1775 (also known as AZD1775), a mitotic inhibitor, has been demonstrated to enhance the anti-tumor effects of DNA damaging agents such as gemcitabine. We evaluated the efficacy of MK-1775 alone or in combination with DNA damaging agents (MMC or oxaliplatin) in PDA cell lines that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Pancreatic Ductal
Share to Drug Synergism

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Inhibitory Concentration 50

Share to Mitomycin

Share to Organoplatinum Compounds

Share to Oxaliplatin

Share to Pyrazoles

Share to Pyrimidinones

Source

Open in PubMed Open full text

Identifiers

PMID: 27616351
DOI: 10.1038/srep33323
PMCID: PMC5018859

Genes

BRCA2
WEE1
FANCC
FANCD2
FANCG
MIA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

WEE1 inhibition in pancreatic cancer cells is dependent on DNA repair status in a context dependent manner.PMID 27616351Read ↗

MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts.Semantic proximity Read ↗

CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancerSemantic proximity Read ↗

Wee1 Rather Than Plk1 Is Inhibited by AZD1775 at Therapeutically Relevant ConcentrationsSemantic proximity Read ↗

The contribution of DNA replication stress marked by high-intensity, pan-nuclear γH2AX staining to chemosensitization by CHK1 and WEE1 inhibitorsSemantic proximity Read ↗

Molecular Pathways: Targeting the Protein Kinase Wee1 in CancerSemantic proximity Read ↗

Wee1 kinase as a target for cancer therapySemantic proximity Read ↗

p21 limits S phase DNA damage caused by the Wee1 inhibitor MK1775Semantic proximity Read ↗

Abrogation of the G2 Checkpoint by Inhibition of Wee-1 Kinase Results in Sensitization of p53-Deficient Tumor Cells to DNA-Damaging AgentsSemantic proximity Read ↗

Myt1 overexpression mediates resistance to cell cycle and DNA damage checkpoint kinase inhibitorsSemantic proximity Read ↗

Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferationSemantic proximity Read ↗

The Fcp1-Wee1-Cdk1 axis affects spindle assembly checkpoint robustness and sensitivity to antimicrotubule cancer drugsSemantic proximity Read ↗

Depletion of RAD17 sensitizes pancreatic cancer cells to gemcitabineSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.